Respiratory Syncytial Virus

Respiratory syncytial virus (RSV) is the second leading cause of infant mortality and a major cause of older adult mortality. At Julius Clinical, we are dedicated to using our full capabilities in support of the testing of novel treatments that can potentially reduce the spread and severity of RSV.

We are a therapeutically focussed CRO that is dedicated to testing novel treatments that might reduce the spread and severity of RSV. We rely on collaborations with world renown scientific leaders, our operational expertise, our proprietary site networks and a partnership with a ReSViNET, which has a proven RSV research track record.

Meet our scientific leader for RSV clinical trials

We collaborate with Prof. dr. Louis Bont, a paediatrician specialized in infectious diseases and immunology at the University Medical Centre (UMC) Utrecht, and Chairman of the ReSViNET foundation. He supervises RSV related studies, such as the RSV GOLD mortality study (funded by the Bill & Melinda Gates Foundation), and is adviser to the World Health Organization (WHO) for RSV vaccine development.

Access to healthcare in sub-Saharan countries remains a challenge, resulting in profound inequities in health in the region. In response to these challenges, Julius Clinical and Julius Global Health (part of the University Medical Center Utrecht) have created Africa Clinical, a network of local clinical investigators and institutes who are committed to improving healthcare and specifically the health of the sub-Saharan population.

Read more

We established ReSViNET in 2014, and since 2018, ReSViNET has been a foundation — a financially and otherwise independent regulated entity. Julius Clinical works closely with ReSViNET to provide operational support to RSV clinical trials and observational studies. Our operational team has extensive experience in coordinating these studies, and ReSViNET has access to sites in countries across the globe, providing fast recruitment and high retention rates.

Read more

Surveillance study, Global


300 Patients | 2 Countries | 3 Sites

Global surveillance study of Respiratory Syncytial Virus (RSV).

Retrospective evaluation, Global


100 Patients | 5 Countries | 5 Sites

Retrospective evaluation of respiratory specimens collected from infants for respiratory syncytial virus (RSV) analysis.

Observational study, Global

4250 Patients | 17 Countries | 19 Sites

Monitoring of RSV to determine the molecular heterogenity of RSV in children.

Our expert RSV research team

We excel operationally, and we speak the language of our Sponsors because we understand the details of RSV clinical trials. Our methodology and approach prioritise flexibility and speed, and our deep knowledge enables us to optimise the execution of RSV trials for our clients.

Leyla kragten
David ong
Jochem hogenhuis

Related webinars


"*" indicates required fields

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Request for proposal

"*" indicates required fields

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
This field is for validation purposes and should be left unchanged.


Twitter Facebook LinkedIn